Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Diffuse Large B-Cell Lymphoma With Combined TP53 mutation and MIR34A methylation: Another “double hit” Lymphoma With Very Poor Outcome?

Fazila Asmar, MD, Christoffer Hother, MD, PhD, Gorjan Kulosman, MD, Marianne B. Treppendahl, MD PhD, Helene Myrtue Nielsen, MSc, Ralfkiaer Ulrik, MSc, Anja Pedersen, Michael B. Møller, MD, DMSc, Elisabeth Ralfkiaer, MD, DMSc, Peter de Nully Brown, MD, Kirsten Grønbæk, MD, DMSc

Blood (2013) 122 (21): 83.

https://doi.org/10.1182/blood.V122.21.83.83

Published: 2013

Journal Articles

Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival

Daisuke Ennishi, MD, PhD, Fong Chun Chan, MSc, David W. Scott, MBChB PhD, Christoffer Hother, MD, PhD, Barbara Meissner, PhD, Merrill Boyle, B.Sc., Ryan D Morin, Laurie H. Sehn, MD, MPH, Marco A. Marra, PhD, Joseph M. Connors, MD, Christian Steidl, MD, Randy D. Gascoyne, MD

Blood (2013) 122 (21): 500.

https://doi.org/10.1182/blood.V122.21.500.500

Published: 2013

Journal Articles

miR34s in Normal and Malignant B-Cells: miR34A Plays a Dominant Role in Normal B-Cells, and aggressive Diffuse Large B-Cell Lymphoma Carry Combined Lesions of TP53, MIR34A , and MIR34B/C

Christoffer Hother, MD, Fazila Asmar, MD, Gorjan Kulosman, MD, Marianne B. Treppendahl, MD, Ditte Reker, Ulrik Ralfkiaer, MSc, Anja Pedersen, Michael B. Møller, MD, DMSc, Peter De Nully Brown, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 296.

https://doi.org/10.1182/blood.V120.21.296.296

Published: 2012

Journal Articles

MicroRNA Profiling in Low-Grade Ocular MALT and Diffuse Large B-Cell Lymphoma: A Role for MYC and NFKB1 Mediated Dysregulation of MicroRNA Expression in Aggressive Disease

Christoffer Hother, MD, Peter Kristian Rasmussen, MD, Tejal Joshi, PhD, Ditte Reker, Ulrik Ralfkiaer, MSc, Christopher Workman, PhD, Peter De Nully Brown, Steffen Heegaard, Prof. MD, Elisabeth Ralfkiaer, Prof., MD, DMSc, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 1600.

https://doi.org/10.1182/blood.V120.21.1600.1600

Published: 2012

Journal Articles

miRNA Profiling in Human Granulopoiesis and in Activated Neutrophils From Skin Window.

Maria Torp Larsen, MD, Christoffer Hother, MD, Mattias Hager, MSc, Corinna Cavan Pedersen, MSc, Lars Jacobsen, MSc, Niels Borregaard, Jack B Cowland

Blood (2012) 120 (21): 2136.

https://doi.org/10.1182/blood.V120.21.2136.2136

Published: 2012

Journal Articles

miRNA Profiling Predicts Survival and Identifies a Novel Putative Oncomir in Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy

Christoffer Hother, MD, Ditte Reker, Konstantions Dimopoulos, MD, Steen Knudsen, PhD, Thomas Jensen, Michael B. Møller, MD, DMSc, Peter De Nully Brown, Elisabeth Ralfkiaer, Prof., MD, DMSc, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 1548.

https://doi.org/10.1182/blood.V120.21.1548.1548

Published: 2012

Journal Articles

Mir-130a-Mediated Downregulation of SMAD4 Contributes to Reduced Sensitivity to TGFβ Stimulation in Promyelocytic Cells,

Mattias Hager, Corinna Cavan Pedersen, Maria Torp Larsen, Mette Klarskov Andersen, MD, Christoffer Hother, MD, Kirsten Grønbæk, MD, DMSc, Hanne Jarmer, Niels Borregaard, Jack B Cowland

Blood (2011) 118 (21): 3383.

https://doi.org/10.1182/blood.V118.21.3383.3383

Published: 2011

Journal Articles

Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML,

Marianne B. Treppendahl, MD, Xiangning Qiu, MD, Alexandra Søgaard, MSc, Cecilie Nandrup-Bus, MSc, Christoffer Hother, MD, Mette Klarskov Andersen, MD, Lars Kjeldsen, MD, PhD, Lars Möllgård, MD, Eva Hellstrom-Lindberg, MD, PhD, Johan Jendholm, MSc, Bo T. Porse, PhD, Peter A. Jones, PhD, DSc, Gangning Liang, PhD, Kirsten Grønbæk, MD, DMSc

Blood (2011) 118 (21): 3450.

https://doi.org/10.1182/blood.V118.21.3450.3450

Published: 2011

Journal Articles

Epigenetic Silencing of a Novel Candidate Tumor Suppressor “miR” Predicts Poor Prognosis In High-Risk MDS and AML.

Marianne B. Treppendahl, MD, Xiangning Qiu, MD, Christoffer Hother, MD, Mette K. Andersen, MD, PhD, Lars Kjeldsen, MD, PhD, Peter Jones, Professor, Gangning Liang, PhD, Kirsten Gr∅nbæk, MD, PhD

Blood (2010) 116 (21): 3629.

https://doi.org/10.1182/blood.V116.21.3629.3629

Published: 2010

NARROW

Diffuse Large B-Cell Lymphoma With Combined TP53 mutation and MIR34A methylation: Another “double hit” Lymphoma With Very Poor Outcome?

Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival

miR34s in Normal and Malignant B-Cells: miR34A Plays a Dominant Role in Normal B-Cells, and aggressive Diffuse Large B-Cell Lymphoma Carry Combined Lesions of TP53, MIR34A , and MIR34B/C

MicroRNA Profiling in Low-Grade Ocular MALT and Diffuse Large B-Cell Lymphoma: A Role for MYC and NFKB1 Mediated Dysregulation of MicroRNA Expression in Aggressive Disease

miRNA Profiling in Human Granulopoiesis and in Activated Neutrophils From Skin Window.

miRNA Profiling Predicts Survival and Identifies a Novel Putative Oncomir in Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy

Mir-130a-Mediated Downregulation of SMAD4 Contributes to Reduced Sensitivity to TGFβ Stimulation in Promyelocytic Cells,

Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML,

Epigenetic Silencing of a Novel Candidate Tumor Suppressor “miR” Predicts Poor Prognosis In High-Risk MDS and AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only